Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017110841) NON-AROMATIC HETEROCYCLIC DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/110841 International Application No.: PCT/JP2016/088024
Publication Date: 29.06.2017 International Filing Date: 21.12.2016
IPC:
C07D 211/86 (2006.01) ,A61K 31/435 (2006.01) ,A61K 31/444 (2006.01) ,A61P 3/04 (2006.01) ,A61P 3/06 (2006.01) ,A61P 3/10 (2006.01) ,A61P 9/10 (2006.01) ,A61P 43/00 (2006.01) ,C07D 401/04 (2006.01) ,C07D 405/14 (2006.01) ,C07D 409/14 (2006.01) ,C07D 413/14 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
211
Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04
with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
80
having two double bonds between ring members or between ring members and non-ring members
84
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
86
Oxygen atoms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
444
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
06
Antihyperlipidemics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
Applicants:
塩野義製薬株式会社 SHIONOGI & CO., LTD. [JP/JP]; 大阪府大阪市中央区道修町3丁目1番8号 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5410045, JP
Inventors:
西浦 祐二 NISHIURA, Yuji; JP
倉橋 香菜 KURAHASHI, Kana; JP
大藪 巨樹 OHYABU, Naoki; JP
佐々木 義一 SASAKI, Yoshikazu; JP
Agent:
山内 秀晃 YAMAUCHI, Hideaki; JP
杉田 健一 SUGITA, Ken-ichi; JP
Priority Data:
2015-24830621.12.2015JP
Title (EN) NON-AROMATIC HETEROCYCLIC DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY
(FR) DÉRIVÉ HÉTÉROCYCLIQUE NON-AROMATIQUE PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE MGAT2
(JA) MGAT2阻害活性を有する非芳香族複素環誘導体
Abstract:
(EN) The invention pertains to a compound shown by formula (I): (in the formula, X is C(=O) or the like, Z is C(=O) or the like, L is a single bond or the like, A is an aromatic carbon ring or the like, R is R6 or B, or the like, R2 is a hydrogen or the like, R3 is a substituted or unsubstituted alkyl or the like, R4a is a hydrogen or the like, R4b is a hydrogen or the like, R5 is a halogen or the like, R6 is a halogen or the like, R7a is a hydrogen or the like, R7b is a hydrogen or the like, R8 is a hydrogen or the like, R9 is a hydrogen or the like, m is 0-5, n is 0-5, and p is 1-6) or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions containing them.
(FR) L'invention concerne un composé représenté par la formule (I) : (dans la formule, X est C(=O) ou similaire ; Z est C(=O) ou similaire, L est une liaison simple ou similaire, A est un cycle carboné aromatique ou similaire, R est R6 ou B, ou similaire, R2 est un atome d'hydrogène ou similaire, R3 est un alkyle substitué ou non substitué ou similaire, R4a est un atome d'hydrogène ou similaire, R4b est un atome d'hydrogène ou similaire, R5 est un atome d'halogène ou similaire, R6 est un atome d'halogène ou similaire, R7a est un atome d'hydrogène ou similaire, R7b est un atome d'hydrogène ou similaire, R8 est un atome d'hydrogène ou similaire ; R9 est un atome d'hydrogène ou similaire, m est compris entre 0 et 5, n est compris entre 0 et 5, et p est compris entre 1 et 6) ou un sel pharmaceutiquement acceptable de ce dernier, et des compositions pharmaceutiques les contenant.
(JA) 本発明は、式(I):(式中、XはC(=O)等、ZはC(=O)等、Lは単結合等、Aは芳香族炭素環等、RはRまたはB等、Rは水素等、Rは置換もしくは非置換のアルキル等、R4aは水素等、R4bは水素等、Rはハロゲン等、Rはハロゲン等、R7aは水素等、R7bは水素等、Rは水素等、Rは水素等、mは0~5、nは0~5、pは1~6)で示される化合物またはその製薬上許容される塩、およびそれらを含有する医薬組成物に関する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
EP3395798US20180353492